In January 2026, Abbott Laboratories shares declined by more than 8% from recent highs, dragging the stock back into what many market commentators now call a "buy zone." Analysts attribute the pullback primarily to broad market volatility and investor trepidation rather than any fundamental weakness at Abbott. Over the first three weeks of the year, the stock underperformed the S&P 500 by roughly 6 percentage points, providing long-term investors an opportunity to acquire a stake at valuation multiples nearing 18 times forward earnings—about 10% below the five-year average P/E ratio for the company.

Abbott reported fourth-quarter revenue of $11.46 billion, marking 4.4% year-over-year growth but falling short of consensus estimates by about 3%. Adjusted EPS of $1.50 matched expectations, bolstered by double-digit expansion in its Medical Devices segment (up 12.3%) and a 14.5% rise in Diabetes Care sales to $2.13 billion. However, Nutrition revenue declined 8.9% to $1.94 billion and Diagnostics dipped 2.5%, triggering a knee-jerk sell-off. Management reiterated full-year Guidance for 6.5%–7.5% organic sales growth and forecast 2026 EPS of $5.55–$5.80, representing roughly 10% midpoint growth over 2025.

Twenty-two brokerage firms cover Abbott, assigning an average rating of Moderate Buy. Within that group, 17 analysts maintain Buy recommendations and two endorse Strong Buy, while three suggest Hold. Over the past week, several major houses reduced their 12-month price targets—Citigroup from $155 to $140, Sanford C. Bernstein from $154 to $125, RBC from $147 to $135 and Goldman Sachs from $152 to $140—but retained constructive stances, underscoring confidence in Abbott’s long-term growth drivers and cash flow generation.

In India, authorities have initiated an investigation into the supply chain of Phensedyl, a codeine-based cough syrup formerly produced by Abbott Healthcare. Although production ceased in December 2024, state officials report that approximately 22 million bottles valued at $55 million were distributed in Uttar Pradesh between April 2024 and March 2025. Seizures of 30,000 bottles hidden in rice sacks and evidence of volumes far exceeding medical demand suggest diversion for non-therapeutic use, introducing a potential reputational and litigation risk for the company’s emerging-markets operations.